Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innate Pharma S.A.

http://www.innate-pharma.com/

Latest From Innate Pharma S.A.

AstraZeneca Pulls Plug On Lumoxiti Due To Low Uptake

Signs of trouble were already emerging in 2020 when Innate backed out of a co-commercialization pact. AstraZeneca plans to discontinue the hairy cell leukemia ADC in July.

Business Strategies Cancer

Sanofi Gains New Innate Program In Expanded Collaboration

Deal Snapshot: Innate will receive 25m up front from Sanofi for an exclusive license to a new natural killer (NK) cell engager program and options to two additional targets.

Deals Cancer

Lacutamab Data Boost Prospects For Innate Pharma

The French biotech has presented positive Phase II data on lacutamab in mycosis fungoides at the EORTC-CLTG meeting in Madrid which looks to have de-risked the asset.

Cancer Clinical Trials

Innate Lead Candidate Fails In Head And Neck Cancer But Partner AZ Offers Hope In NSCLC

Innate’s lead candidate has reached the end of the road in head and neck carcinoma after a disappointing interim Phase III trial analysis but hope remains that a combination with partner AstraZeneca's Imfinzi could succeed elsewhere.

Clinical Trials Cancer
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
UsernamePublicRestriction

Register